Histiocytosis, Langerhans-Cell is a specific type of histiocytosis. It's caused by an overgrowth of Langerhans cells, which are a type of immune cell. These cells normally help fight infections. When they grow too much, they can cause problems in different parts of the body, like the skin, lungs, or bones. It's sometimes called Histiocytosis X.
Every report comes from a Lived member, sent anonymously.
Have you tried Vinblastine for Langerhans-Cell Histiocytosis?
Langerhans cell histiocytosis (LCH) is a rare disorder in which a type of immune cell builds up where it shouldn't. These abnormal cells, called LCH cells, gather in tissue and can damage it or form lesions, most often in bone but also in the skin, lungs, pituitary gland, lymph nodes, liver, spleen or bone marrow. It is most common in young children, but adults can develop it too. Older names for its different patterns include histiocytosis X, eosinophilic granuloma, Hand-Schüller-Christian disease and Letterer-Siwe disease. LCH ranges from a single bone spot that heals with little treatment to widespread disease that is life-threatening. Doctors describe it as single-system (one organ or body system, most often bone) or multisystem. Involvement of the liver, spleen or bone marrow is called high-risk because those sites carry a real danger to life; other sites are called low-risk because they rarely threaten life, though they can still leave lasting damage. Experts still debate whether LCH is a true cancer, but it is now understood as a disorder of blood-forming cells, and it is treated by cancer and blood specialists, often with cancer medicines. Symptoms depend on where it is. A painful lump or swelling over the skull, jaw, ribs, spine or a long bone is common. In infants it may look like stubborn cradle cap or a rash in skin folds. Other signs include swollen gums or loose teeth, a draining ear, swollen glands, a dry cough or shortness of breath, and strong thirst with frequent urination.
Most LCH cells carry a change in a gene that controls cell growth, most often a variant in the BRAF gene, with others in related genes along the same growth-signaling pathway. These changes arise in the abnormal cells during life; LCH is not usually inherited and is not contagious. In children with the BRAF variant, the disease is more often widespread and harder to treat. Researchers have found a few associations in children: a family history of cancer or thyroid disease, a parent exposed to certain solvents or workplace dusts, infections as a newborn, and Hispanic background. These raise the odds slightly and do not mean a parent caused the illness. In adults, LCH limited to the lungs is closely tied to smoking. More than 90 percent of adults with lung LCH are young adults who smoke, often heavily.
Because LCH can look like many other problems, from a bone cyst to eczema to an infection, a biopsy is the key step. A small piece of the affected bone, skin or other tissue is examined under a microscope, and stains for proteins called CD1a and langerin confirm that the cells are LCH cells. The sample is often tested for the BRAF variant, which can help guide treatment. Once LCH is confirmed, doctors look for every place it is active, because that decides the risk group and the treatment. This usually includes blood counts and liver tests, a urine test, x-rays of the whole skeleton or a PET scan (positron emission tomography, a scan that shows where disease is active), and a chest x-ray. Other tests depend on symptoms: MRI of the brain and pituitary for thirst, growth or neurologic changes; a high-resolution chest CT and breathing tests for lung disease; a bone marrow biopsy if blood counts are low; and hearing tests when the ears are involved. A water deprivation test can confirm diabetes insipidus, a loss of a pituitary hormone that helps the kidneys hold on to water, which causes strong thirst and heavy urination and is unrelated to blood-sugar diabetes.
Treatment depends on the risk group, the sites involved and the person's age. Some forms need little or no treatment: a skin rash in an infant may clear by itself within the first year, and some single bone lesions need nothing more than the biopsy and careful watching. A single bone lesion is often treated by scraping it out (curettage), sometimes with a steroid injection. Low-dose radiation is reserved for lesions that press on nearby structures or cannot be treated another way. When disease involves several bones, more than one system, high-risk organs, or bones near the base of the skull (where it raises the risk of pituitary and brain problems), the usual first treatment is chemotherapy with vinblastine, a chemotherapy drug given by vein, plus prednisone, a steroid taken by mouth. In children with multisystem disease, giving this for about 12 months rather than six lowered the chance of the disease coming back. People whose disease does not respond or keeps returning may receive other chemotherapy drugs such as cytarabine or cladribine. Targeted medicines have changed care for harder cases. BRAF inhibitors such as vemurafenib and dabrafenib block the signal from the BRAF variant, and MEK inhibitors block the same growth pathway further along. Cobimetinib (Cotellic), a MEK inhibitor taken as a tablet, is FDA-approved for adults with histiocytic disorders including LCH. These drugs often work quickly, but in studies most people relapsed after stopping BRAF inhibitors, and the same question is being studied for MEK inhibitors, so how long to continue them is still being worked out. A stem cell transplant, or a liver or lung transplant for severe organ damage, is rarely needed. For adults with LCH in the lungs, quitting smoking is the most important treatment, and lung damage tends to keep worsening when smoking continues. After quitting, the lungs may improve, stabilize or still worsen, so some people also need medication. Diabetes insipidus is managed with desmopressin, a replacement for the missing hormone, which treats the symptoms but does not reverse the pituitary damage.
The outlook depends mostly on which organs are involved and how well the disease responds in the first weeks of treatment. People with single-system or low-risk disease almost never die of LCH. Children with high-risk disease face a real threat to life, though outcomes have improved, with about 84 percent survival in a large trial using 12 months of chemotherapy. LCH often comes back after treatment ends, usually in bone, skin or the ears, and often within a year of stopping treatment. This is called reactivation. It happens in about 1 in 10 people with a single lesion, about 1 in 4 with several bone lesions, and about half of those with low-risk multisystem disease. A reactivation is usually treatable, but repeated episodes add up. The longer-term concern is lasting damage, from the disease or its treatment, which is more common after multisystem disease. These effects include diabetes insipidus, loss of other pituitary hormones that affect growth and puberty, hearing loss, missing teeth, bone deformity, lung scarring and, rarely, a slowly progressive neurologic condition that affects balance, speech, learning and behavior. Some can appear years after the disease seems gone. For this reason, follow-up with a team experienced in LCH continues for many years, with periodic exams, imaging, and hormone, hearing and lung checks as needed. Adults who had LCH as children should not smoke, and adults with LCH have a higher risk of some other cancers, so routine cancer screening matters.
See a doctor about a lump or swelling on a bone that hurts or keeps growing, a rash in an infant that does not respond to usual care, chronic ear drainage, swollen gums or loose teeth in a child, or a cough and breathlessness in a young adult who smokes. A baby or young child with a rash or bone lesion who also has a swollen belly, yellow skin or eyes, easy bruising or bleeding, repeated fevers or frequent infections should be seen promptly (the same day or next), since these can mean the liver, spleen or bone marrow is involved. If you or your child has had LCH, contact the care team promptly about new bone pain or swelling, a returning rash, unusual thirst or frequent urination, slowing growth, hearing changes, or new problems with balance, coordination, speech or behavior, since these can be signs that the disease has come back or caused new damage. During chemotherapy, follow the team's instructions for fever. For anyone with lung LCH, sudden sharp chest pain or sudden shortness of breath can mean a collapsed lung and needs emergency care right away.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with Langerhans-Cell Histiocytosis is like, what's helped you, or ask the community a question.